成功实施了一项利益相关者参与计划,用于制药流行病学研究
Sara J Cromer1,2,3, Barbara Steiner2, Cassie York3
1Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Pharmacoepidemiology and drug safety
|November 20, 2023
概括
让各种各样的利益相关者参与复杂的药物流行病学研究是可行的和有益的. 患者和临床医生的参与改善了研究设计和传播,证明了利益相关方参与促进健康研究的价值.
科学领域:
- 药学流行病学 药学流行病学
- 医疗保健服务研究 医疗服务研究
- 患者参与 患者参与
背景情况:
- 药物流行病学研究通常涉及复杂的方法.
- 利益相关者在这一领域的参与尚未得到充分记录.
- 需要了解如何有效地让利益相关者参与严格的研究.
研究的目的:
- 描述一种方法,让利益相关者参与多年制药流行病学研究计划.
- 分享从涉及不同研究经验的患者和临床医生中学到的经验教训.
- 评估利益相关者参与对研究质量和成果的影响.
主要方法:
- 招募和补偿患者和临床医生的利益相关者.
- 提供了观察性研究和药物流行病学方法的培训.
- 每年2至3次进行虚拟利益相关者会议,并提供准备材料.
主要成果:
- 高出席率 (89%-100%) 和所有利益相关者的参与度.
- 利益相关者报告了积极的经验,满意度和奉献精神.
- 贡献包括优先考虑研究问题,优化证据简报,并就传播提供建议.
结论:
- 在复杂的药物流行病学研究中,利益相关者的参与是可行的和可以接受的.
- 参与积极影响研究项目,从设计到传播.
- 这种方法提高了研究结果的相关性和适用性.
相关概念视频
Pharmacovigilance
857
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
857
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
130
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
130
Preclinical Development: Overview
4.4K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.4K
Analysis of Population Pharmacokinetic Data
266
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
266
Clinical Trials: Overview
3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
Drug Discovery: Overview
8.0K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.0K


